Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolio

Xerox to press ahead despite HP's poison pill plan against takeover offer

Published 02/21/2020, 10:30 AM
Updated 02/21/2020, 10:34 AM
Xerox to press ahead despite HP's poison pill plan against takeover offer
XRX
-
HPQ
-

(Reuters) - Xerox (NYSE:XRX) Holdings Corp said on Friday it would continue to pursue HP Inc (NYSE:HPQ), even after the PC maker said it would implement a poison pill plan to shield itself against a takeover offer from the U.S. printer maker.

"Despite the HP board's intention to deny shareholders the chance to choose for themselves, we will press ahead with our previously announced tender offer and electing our slate of highly qualified director candidates," Xerox said.

It raised its offer earlier this month by $2 to $24 per share, following several rejections of its previous buyout offers by HP.

HP on Thursday said the implementation of the stockholder rights plan, which has a one-year expiration period, aims to stop investors from amassing more than 20% stake in the company.

That leaves Xerox with one realistic alternative for its takeover plans. It will have to go ahead with its plans to replace HP's board with its own nominees in a shareholder vote during the latter's upcoming annual meeting.

Xerox said in January it plans to nominate 11 independent candidates to HP's board.

HP did not immediately respond to Reuters' request for comment.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.